Low Dose Naltrexone (LDN) was first FDA approved in the 1984 in doses of 50 to 300mg for
addiction. Not soon after that we began to see it also had a notable immune response. With the help of many studies and clinicians it was found that when administered at much lower doses up to 10mg, LDN has an immune modulating effect.
How does it work?
At higher doses Naltrexone blocks opiate receptors targeted to help with addiction. At lower
doses it has been shown to work on up to 12 immunomodulatory receptors to reduce inflammatory immune cell signaling. It improves the immune system response and increases endorphins that stimulate the immune system and reduce inflammation. LDN operates as a novel anti-inflammatory and immunomodulator agent to improve the lives of so many burdened with auto-immune disorders.
What is the dose?
LDN works best when it is titrated up. Starting doses range from 0.5 to 1.5mg and are titrated up weekly. Dosing is very patient specific and our pharmacists can work with you and your doctor to help you find your “sweet spot”. LDN is very well tolerated in most patients. A slow titration can help alleviate any side effects that are usually only present in the beginning. Most patients have seen results within the first two months.
What conditions has it treated?
- Autoimmune disorders
- Inflammatory Bowel Disease (Crohn’s/Ulcerative Colitis)
- Multiple Sclerosis
- Lyme Disease
- Chronic Viral Infections
- Mast Cell Activation Syndrome (MCAS)
- Hashimoto’s Thyroiditis
- Grave’s Disease
- Parkinson’s Disease
- Diabetes Type I
- Anxiety and Depression
- Chronic Pain
- Possible Side Effects:
- Vivid dreams
- Mild Headache
- GI upset
Our dosage forms:
- Sublingual drops
- Troches, lozenges
* All of our dosage forms are hypoallergenic being gluten, corn, soy, dye, and dairy free. Vegan capsules are available upon request as well!
The LDN Ebook: Low Dose Naltrexone (Ldn) Testimonials from Patients ... https://www.amazon.com/LDN-eBook-Testimonials-Prescribers-Pharmacists-
“The LDN 2022 Guides.” LDN Research Trust, https://ldnresearchtrust.org/2022_LDN_Guides. Toljan, Karlo, and Bruce Vrooman. “Low-Dose Naltrexone (LDN)-Review of Therapeutic
Medical sciences (Basel, Switzerland) vol. 6,4 82. 21 Sep. 2018,